Literature DB >> 15157566

Endocrine autoantibodies.

Devasenan Devendra1, Liping Yu, George S Eisenbarth.   

Abstract

The autoantibody assays that exist and that are being refined are of increasing importance to a broad spectrum of endocrine disorders. This is particularly true for type IA diabetes, which is one of the best-studied organ-specific autoimmune diseases. Autoantibodies are used as valuable markers in prediction and prevention studies of type IA diabetes. Autoantibodies related to other endocrine organs are also important because multiple related autoimmune endocrine and non-endocrine disorders are increased in frequency in patients and their families with autoimmunity. The availability of highly sensitive and specific autoantibody assays for the various endocrine disorders can allow physicians to better diagnose and promptly treat these conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15157566     DOI: 10.1016/j.cll.2004.01.012

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  3 in total

1.  Pancreatic duodenal homeobox 1 protein is a novel beta-cell-specific autoantigen for type I diabetes.

Authors:  Shi-Wu Li; Vijay Koya; Yi Li; William Donelan; Peng Lin; Westley H Reeves; Li-Jun Yang
Journal:  Lab Invest       Date:  2009-11-09       Impact factor: 5.662

2.  Autoantibodies against Cytochrome P450 Side-Chain Cleavage Enzyme in Dogs (Canis lupus familiaris) Affected with Hypoadrenocorticism (Addison's Disease).

Authors:  Alisdair M Boag; Michael R Christie; Kerry A McLaughlin; Harriet M Syme; Peter Graham; Brian Catchpole
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

3.  Multiplex Autoantibody Detection in Patients with Autoimmune Polyglandular Syndromes.

Authors:  Elena N Savvateeva; Marina Yu Yukina; Nurana F Nuralieva; Marina A Filippova; Dmitry A Gryadunov; Ekaterina A Troshina
Journal:  Int J Mol Sci       Date:  2021-05-23       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.